

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Keymed Biosciences Inc.**  
**康諾亞生物醫藥科技有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2162)**

## **VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR CM336**

### **Introduction**

The board of directors (the “**Board**”) of Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that on November 17, 2024, Keymed Biosciences (Chengdu) Co., Ltd. (康諾亞生物醫藥科技(成都)有限公司) (a wholly-owned subsidiary of the Company, “**Chengdu Keymed**”) and Platina Medicines Ltd (“**PML**”) have entered into an exclusive license agreement (the “**License Agreement**”). The License Agreement grants PML the exclusive right to develop, manufacture and commercialize CM336 globally excluding Mainland China, Hong Kong, Macau and Taiwan (the “**Licensed Region**”). CM336 is an in-house developed bispecific antibody of the Company.

### **Principal Terms of the License Agreement**

Subject to terms and conditions of the License Agreement, PML is granted an exclusive license for the research, development, registration, manufacturing, and commercialization of CM336 in the Licensed Region. In return, the Group shall receive an upfront and near-term payment of US\$16 million and a minority equity interest in Ouro Medicines, LLC (“**Ouro Medicines**”) as part of the consideration. Ouro Medicines is the parent company of PML and owns 100% of the equity interest in PML. The Group may also receive additional payments of up to US\$610 million subject to achievement of certain clinical, regulatory and commercial milestones and is also entitled to receive tiered royalties on net sales of CM336 and related products from PML. The Group is obliged to provide assistance to facilitate technology and knowledge transfer. Except as otherwise agreed, PML will be responsible for bearing all costs for activities associated with the development of CM336 in the Licensed Region.

In connection with the License Agreement, PML and the Group will enter into a clinical supply agreement under which PML will source clinical supply of CM336 drug product from the Group.

## **Reasons for and Benefits of the License Agreement**

The Board believes that entering the License Agreement is in the best interests of the Company and its shareholders as a whole. The Company will also leverage on this opportunity to further strengthen its global cooperation network through its innovative collaboration model and maximize the scientific and commercial value of the Company's technology platforms.

### **About CM336**

CM336 is a BCMAxCD3 bispecific antibody that can simultaneously target and identify and specifically bind both BCMA on the surface of target cells and the CD3 receptor on the surface of T cells to recruit immune T cells to the vicinity of the target cells, thereby inducing T-cell dependent cellular cytotoxicity (TDCC) to eliminate the target cells.

As of the date of this announcement, we have been proceeding with a multi-center, open-label Phase I/II clinical study to assess CM336 injection in treating patients with relapsed or refractory multiple myeloma.

Furthermore, based on the clinical effects observed in multiple myeloma indication, the Company believes that CM336 could represent a promising new therapeutic option for autoimmune diseases by eliminating plasma cells that secrete pathogenic antibodies.

### **About Ouro Medicines and PML**

Ouro Medicines is a limited liability company incorporated in March 2024 in Delaware, the United States. It is principally engaged in drug development and commercialization. Upon closing of the License Agreement and on a fully diluted basis, it will be held 42% by Monograph Capital, a healthcare and life sciences investment firm. No other shareholder holds 30% or more of the equity interests in Ouro Medicines.

Ouro Medicines's wholly-owned subsidiary, PML, is a limited liability company incorporated in October 2024 in the United Kingdom. It is principally engaged in drug development and commercialization, including the development and commercialization of CM336 in the Licensed Region. Dr. Bo CHEN (the Company's chairman and executive director) has been nominated as one of the five members of Ouro Medicines's board of directors. To the best knowledge and belief of the Company, Ouro Medicines, PML and their respective shareholders are independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

As none of the applicable percentages under Rule 14.07 of the Listing Rules in relation to the transactions under License Agreement is 5% or more, the transactions under the License Agreement are not subject to any of the reporting, announcement or shareholders' approval requirements under Chapter 14 of the Listing Rules.

This announcement is made by the Company on a voluntary basis to provide information to shareholders and potential investors of the Company. There is no assurance that the Company, Ouro Medicines, or PML will ultimately develop, launch and/or commercialize CM336 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Keymed Biosciences Inc.**  
**Dr. Bo CHEN**  
*Chairman*

Hong Kong, November 17, 2024

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive Directors.*